Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 103,635 shares at $2.52 ($265K) on 2014-09-23, disclosed to the SEC on 2014-09-24.
Scheduled sale ($265k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.49 | 500 | $1K | 0.5% |
| 2 | $2.50 | 600 | $2K | 0.6% |
| 3 | $2.51 | 1,500 | $4K | 1.4% |
| 4 | $2.52 | 799 | $2K | 0.8% |
| 5 | $2.53 | 3,500 | $9K | 3.3% |
| 6 | $2.54 | 300 |
| $762 |
| 0.3% |
| 7 | $2.55 | 300 | $765 | 0.3% |
| 8 | $2.56 | 981 | $3K | 0.9% |
| 9 | $2.57 | 3,000 | $8K | 2.9% |
| 10 | $2.58 | 27,400 | $71K | 26.7% |
| 11 | $2.59 | 2,793 | $7K | 2.7% |
| 12 | $2.60 | 3,901 | $10K | 3.8% |
| 13 | $2.61 | 1,408 | $4K | 1.4% |
| 14 | $2.62 | 2,635 | $7K | 2.6% |
| 15 | $2.63 | 2,200 | $6K | 2.2% |
| 16 | $2.50 | 3,900 | $10K | 3.7% |
| 17 | $2.51 | 15,728 | $39K | 14.9% |
| 18 | $2.52 | 722 | $2K | 0.7% |
| 19 | $2.53 | 2,600 | $7K | 2.5% |
| 20 | $2.54 | 3,300 | $8K | 3.2% |
| 21 | $2.55 | 14,118 | $36K | 13.6% |
| 22 | $2.56 | 9,250 | $24K | 8.9% |
| 23 | $2.57 | 600 | $2K | 0.6% |
| 24 | $2.58 | 1,600 | $4K | 1.6% |
| Total | $2.56 avg | 103,635 | $265K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |